Medical organizations and physicians challenged FDA actions that expanded access to mifepristone. The Supreme Court held that they lacked Article III standing. The plaintiffs did not prescribe or use the drug, and federal conscience protections allowed doctors to decline participation in abortions. Their asserted injuries depended on speculative chains of decisions by patients and other medical professionals, while organizational expenditures undertaken in response to the policy did not create standing. Because the plaintiffs had not shown a concrete injury caused by the FDA and redressable by the requested relief, the judgment was reversed.